93 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
4 Oct 22
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
8:23am
Exhibit 99.1
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats … antibody for seasonal and pandemic influenza viruses –
– Multi-year contract also allows for potential total investment of up to $1 billion
8-K
EX-99.1
VIR
Vir Biotechnology Inc
10 Apr 20
Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture ofSARS-COV-2 Antibodies for Potential COVID-19 Treatment
8:01am
for Vir’sSARS-CoV-2 monoclonal antibody (mAb) program.
“We are proud to be working as a partner with Vir in their response to the globalCOVID-19 pandemic,” said … ) and its letter of intent with Biogen, Inc. (Nasdaq: BIIB).
“Given the trajectory of theCOVID-19 pandemic, our expectation
8-K
VIR
Vir Biotechnology Inc
4 Oct 22
Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats
8:23am
to protect against seasonal and pandemic influenza. The development of VIR-2482 under the BARDA Agreement will include a Phase 2 pre-exposure prophylaxis … of influenza illness or possibly supporting medical countermeasures for other pathogens of pandemic potential. The BARDA Agreement has an initial term
8-K
EX-99.2
VIR
Vir Biotechnology Inc
28 Jan 21
Other Events
4:05pm
and GSK, share the view that we should pursue all possibilities to help end the pandemic and maximize the number of lives that can be saved. This trial … community with further data on the important role these therapies could play in reducing the impact of this devastating pandemic.”
Bamlanivimab alone has
8-K
EX-99.1
VIR
Vir Biotechnology Inc
21 May 21
CORRECTION — EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology’s
3:38pm
, development, GSK, said: “As the COVID-19 pandemic continues and the virus generates new variants of concern, including those that recently emerged … in need and help bring an end to the pandemic.”
The CHMP reached its opinion following a review of data including an interim analysis of efficacy
8-K
EX-99.1
6i613n uto
19 Feb 21
GSK and Vir Biotechnology Expand Coronavirus Collaboration to Advance New Therapeutics for Influenza and Other Respiratory Viruses
5:03pm
8-K
EX-99.1
z1zzejp24onreln1on
3 Nov 22
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results
4:06pm
8-K
EX-99.1
zhekx1pl8j5607hqe
11 Aug 20
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2020 Financial Results
4:05pm
8-K
7s9448hixodb9zo6dpj2
3 Oct 23
Entry into a Material Definitive Agreement
8:01am
8-K
EX-99.1
ak23u627fout
27 May 21
GSK and Vir Biotechnology Announce Sotrovimab (VIR-7831) Receives
4:55pm
8-K
EX-99.1
8tubp8ny
26 Mar 20
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
4:01pm
8-K
EX-99.1
o71r0uzgqi3qcriw96b
6 Apr 20
Entry into a Material Definitive Agreement
8:02am
8-K
EX-99.1
cxhgo
25 Mar 22
Other Events
4:10pm
8-K
EX-99.1
32c8a4eqn5kcb0bs2p5g
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
8-K
EX-99.1
k4smfew
12 May 20
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2020 Financial Results
4:05pm